文献速递药物不良反应与药物警戒

COVID-19疫苗真实世界监测:行业专家对成功、挑战与未来机遇的观点

Real-World Monitoring of COVID-19 Vaccines: An Industry Expert View on the Successes, Challenges, and Future Opportunities.
PubMed 文献 · Drug Saf · 2023-04-11

来自主要疫苗开发商的药物警戒负责人总结了COVID-19大流行在药物警戒和药物流行病学领域的经验,旨在提高对疫苗开发商间合作的认识,强调共同挑战,倡导解决方案,并就真实世界安全性与有效性、安全报告与评估及监管提交提出未来建议。为实现及时评估,实施了多申办方研究平台,在广泛地理区域快速招募;未来可通过地理灵活的共同方案和/或联合公司赞助的多疫苗研究及建设低收入/中等收入国家哨点站点获得更多收益。安全报告、信号检测与评估因不良事件报告数量空前而极具挑战,需要新方法管理增加的报告量同时保持快速识别和响应可能影响每种疫苗获益-风险特征的新数据的能力;全球卫生当局提交、信息请求和不同监管要求给监管机构和行业带来重大负担,行业对安全报告要求的共识和与监管机构的联合会议显著减轻了所有利益相关者的负担。

要点

  • 多申办方研究平台可实现COVID-19疫苗真实世界安全性与有效性的快速评估。
  • 未来应发展地理灵活的共同方案和联合赞助研究,并建设低收入/中等收入国家哨点站点。
  • 行业共识与监管联合会议可减轻安全报告和监管提交的负担。

核心结论

  • 多利益相关方合作和监管共识可提升疫苗真实世界监测效率并减轻报告负担。
  • 最具影响力的创新应迅速实施并扩展到其他疫苗和治疗药物。

研究设计与样本

  • 本文为行业专家观点总结,作者来自主要疫苗开发商的药物警戒负责人。

主要发现

  • 多申办方研究平台实现了广泛地理区域的更快招募。
  • 空前的不良事件报告数量使安全报告、信号检测与评估尤为挑战。
  • 全球卫生当局提交、信息请求和不同监管要求给监管机构和行业带来显著负担。
  • 行业对安全报告要求的共识和与监管机构的联合会议显著减轻了所有利益相关者的负担。

临床怎么用

  • 可借鉴多申办方研究平台模式开展疫苗真实世界安全性与有效性评估。
  • 推动行业共识和与监管机构联合会议以简化安全报告和监管提交。
  • 考虑建设低收入/中等收入国家哨点站点以增强全球监测能力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pharmacovigilance leaders from major vaccine developers describe the learnings from the coronavirus disease 2019 (COVID-19) pandemic in the area of pharmacovigilance and pharmacoepidemiology. The authors aim to raise awareness of the co-operation among vaccine developers, highlight common challenges, advocate for solutions, and propose recommendations for the future in the areas of real-world safety and effectiveness, safety reporting and evaluation, and regulatory submissions. To enable timely evaluation of real-world safety and effectiveness, multi-sponsor study platforms were implemented, resulting in quicker recruitment over wide geographical areas. Future gains could be derived by developing geographically flexible, common protocols and/or joint company-sponsored studies for multiple vaccines and a collective strategy to build low/middle-income country (LMIC) sentinel sites. Safety reporting, signal detection and evaluation was particularly challenging given the unprecedented number of adverse events reported. New methods were required to manage increased report volume while maintaining the ability to quickly identify and respond to new data that could impact the benefit-risk profile of each vaccine. Worldwide health authority submissions, requests for information and differing regulatory requirements imposed significant burden on regulators and industry. Industry consensus on the safety reporting requirements and joint meetings with regulatory authorities markedly reduced this burden for all stakeholders. The most impactful innovations should be undertaken rapidly and expanded to other vaccines and therapeutics, with a multi-stakeholder approach. The authors of this paper make future recommendations and have launched an initiative named BeCOME (Beyond COVID Monitoring Excellence) with a focus on actions in each of the highlighted areas.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Bauchau V, Davis K, Frise S, et al. Real-World Monitoring of COVID-19 Vaccines: An Industry Expert View on the Successes, Challenges, and Future Opportunities. Drug Saf. 2023. PMID: 37040044. doi:10.1007/s40264-023-01290-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。